Plant Name: Corydalis bungeanae herba
Taxonomic Information:
Plant ID: NPO29676
Plant Latin Name: Corydalis bungeanae herba
Taxonomy Genus: Corydalis
Taxonomy Family: Papaveraceae
Plant External Links:
NCBI TaxonomyDB:
n.a.
Plant-of-the-World-Online:
n.a.
Geographical Distribution
See the Plant Occurrence Worldwide with Latitude and Longitude Available
Collective Molecular Activities of the Plant
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Target Proteins
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Cytochrome P450 family 2 | CYP2D6 | Cytochrome P450 2D6 | P10635 | CHEMBL289 |
| Cytochrome P450 family 2 | CYP2C19 | Cytochrome P450 2C19 | P33261 | CHEMBL3622 |
| Small molecule receptor (family A GPCR) | DRD1 | Dopamine D1 receptor | P21728 | CHEMBL2056 |
| Small molecule receptor (family A GPCR) | DRD2 | Dopamine D2 receptor | P14416 | CHEMBL217 |
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| BP | Unclassified; | GO:0021853; cerebral cortex GABAergic interneuron migration | 3.216E-07 | 1.718E-03 | DRD1, DRD2 |
| BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 4.823E-07 | 1.718E-03 | CYP2C19, CYP2D6 |
| BP | GO:0008152; metabolic process | GO:0017144; drug metabolic process | 5.521E-07 | 1.718E-03 | CYP2C19, CYP2D6, DRD1, DRD2 |
| BP | GO:0023052; signaling | GO:0051584; regulation of dopamine uptake involved in synaptic transmission | 9.002E-07 | 2.178E-03 | DRD1, DRD2 |
| BP | GO:0032501; multicellular organismal process | GO:0030432; peristalsis | 1.447E-06 | 3.150E-03 | DRD1, DRD2 |
| BP | GO:0032502; developmental process | GO:0021756; striatum development | 1.768E-06 | 3.412E-03 | DRD1, DRD2 |
| BP | GO:0007610; behavior | GO:0007625; grooming behavior | 2.121E-06 | 3.412E-03 | DRD1, DRD2 |
| BP | GO:0050896; response to stimulus | GO:0060134; prepulse inhibition | 2.507E-06 | 3.412E-03 | DRD1, DRD2 |
| BP | GO:0009987; cellular process | GO:0060158; phospholipase C-activating dopamine receptor signaling pathway | 2.507E-06 | 3.412E-03 | DRD1, DRD2 |
| MF | GO:0060089; molecular transducer activity | GO:0004952; dopamine neurotransmitter receptor activity | 2.121E-06 | 3.412E-03 | DRD1, DRD2 |
| MF | GO:0005488; binding | GO:0035240; dopamine binding | 2.507E-06 | 3.412E-03 | DRD1, DRD2 |
| BP | GO:0007610; behavior | GO:0048148; behavioral response to cocaine | 6.104E-06 | 6.041E-03 | DRD1, DRD2 |
| BP | GO:0050896; response to stimulus | GO:0001975; response to amphetamine | 1.044E-05 | 9.880E-03 | DRD1, DRD2 |
| CC | GO:0043226; organelle | GO:0097730; non-motile cilium | 1.592E-05 | 1.195E-02 | DRD1, DRD2 |
| MF | GO:0003824; catalytic activity | GO:0008395; steroid hydroxylase activity | 1.800E-05 | 1.307E-02 | CYP2C19, CYP2D6 |
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 3.175E-05 | 1.868E-02 | CYP2C19, CYP2D6 |
| CC | GO:0044422; organelle part | GO:0060170; ciliary membrane | 1.088E-04 | 4.558E-02 | DRD1, DRD2 |
| MF | GO:0005488; binding | GO:0020037; heme binding | 2.592E-04 | 6.882E-02 | CYP2C19, CYP2D6 |
| CC | GO:0016020; membrane | GO:0031090; organelle membrane | 3.901E-04 | 8.849E-02 | CYP2C19, CYP2D6, DRD1, DRD2 |
| CC | GO:0016020; membrane | GO:0005789; endoplasmic reticulum membrane | 4.168E-04 | 8.987E-02 | CYP2C19, CYP2D6, DRD1 |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10 KEGG Pathways (ordered by adjusted p-value)
Detailed Information of Enriched KEGG Pathways
| Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|---|
| 09160 Human Diseases | 09164 Substance dependence | hsa05030 | Cocaine addiction | 3.517E-05 | 6.306E-04 | DRD1, DRD2 |
| 09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00982 | Drug metabolism - cytochrome P450 | 7.007E-05 | 6.306E-04 | CYP2D6, CYP2C19 |
| 09140 Cellular Processes | 09144 Cellular community - eukaryotes | hsa04540 | Gap junction | 1.142E-04 | 6.851E-04 | DRD1, DRD2 |
| 09150 Organismal Systems | 09156 Nervous system | hsa04726 | Serotonergic synapse | 1.851E-04 | 8.331E-04 | CYP2D6, CYP2C19 |
| 09150 Organismal Systems | 09156 Nervous system | hsa04728 | Dopaminergic synapse | 2.456E-04 | 8.842E-04 | DRD1, DRD2 |
| 09160 Human Diseases | 09164 Substance dependence | hsa05034 | Alcoholism | 4.723E-04 | 1.215E-03 | DRD1, DRD2 |
| 09160 Human Diseases | 09163 Neurodegenerative diseases | hsa05012 | Parkinson's disease | 2.975E-04 | 8.926E-04 | DRD1, DRD2 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04024 | cAMP signaling pathway | 5.833E-04 | 1.312E-03 | DRD1, DRD2 |
| 09130 Environmental Information Processing | 09133 Signaling molecules and interaction | hsa04080 | Neuroactive ligand-receptor interaction | 1.126E-03 | 2.252E-03 | DRD1, DRD2 |
| 09100 Metabolism | 09103 Lipid metabolism | hsa00591 | Linoleic acid metabolism | 5.788E-03 | 1.042E-02 | CYP2C19 |
Human Diseases Associated with the Target Proteins of the Plant
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
|---|---|---|---|
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | DRD1; |
| I00-I99: Diseases of the circulatory system | Pulmonary hypertension | I27.0, I27.2 | DRD2; |
| C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | DRD2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Bipolar disorder | F31, F40-F42 | DRD2; |
| NA: NA | Benign prostatic hypertrophy | NA | DRD2; |
| C00-D49: Neoplasms | Breast cancer | C50 | DRD2; |
| NA: NA | Schizoaffective disorders | NA | DRD2; |
| J00-J99: Diseases of the respiratory system | Bronchitis | J20-J21, J42 | DRD2; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Carcinoid syndrome | E34.0 | DRD2; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Fibrosis | L90.5 | DRD2; |
| K00-K95: Diseases of the digestive system | Gastrointestinal problems | K30-K31, Q40-Q41 | DRD2; |
| J00-J99: Diseases of the respiratory system | Chronic obstructive pulmonary disease | J40-J44, J47 | DRD2; |
| I00-I99: Diseases of the circulatory system | Cardiotonic | I50 | DRD2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Sexual dysfunction | F52 | DRD2; |
| I00-I99: Diseases of the circulatory system | Cerebrovascular ischaemia | I61-I63 | DRD2; |
| I00-I99: Diseases of the circulatory system | Hypotension | I95 | DRD2; |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | DRD2; |
| I00-I99: Diseases of the circulatory system | Cardiac failure | I50 | DRD2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CYP2D6; DRD2; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Depressive fatigue | R53.82 | DRD2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cocaine addiction | F14.2 | DRD1; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | DRD1; |
| NA: NA | Hyperaemia | NA | DRD2; |
| NA: NA | False perceptions | NA | DRD2; |
| O00-O9A: Pregnancy, childbirth and the puerperium | Excessive bleeding following childbirth and spontaneous or elective abortion | O04 | DRD1; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Schizophrenia | F20 | DRD1; DRD2; |
| G00-G99: Diseases of the nervous system G00-G99 | Migraine | G43 | CYP2D6; |
| NA: NA | Corneal vascularity | NA | DRD2; |
| H00-H59: Diseases of the eye and adnexa | Ophthalmic disease | H00-H59 | DRD2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Dementia | F01-F07 | DRD1; |
| K00-K95: Diseases of the digestive system | Dermal necrosis | K05 | DRD2; |
| NA: NA | Peripheral vasoconstriction | NA | DRD2; |
| G00-G99: Diseases of the nervous system G00-G99 | Migraine headaches | G43 | DRD2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Substance dependence | F10-F19 | DRD1; DRD2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Major depressive disorder | F32, F33, M32 | DRD2; |
| NA: NA | Malignant essential hypertension | NA | DRD2; |
| NA: NA | Malignant phaeochromocytoma | NA | DRD2; |
| O00-O9A: Pregnancy, childbirth and the puerperium | Postpartum haemorrhage | O72 | DRD2; |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | DRD2; |
| A00-B99: Certain infectious and parasitic diseases | Malaria | B54 | CYP2D6; |
| I00-I99: Diseases of the circulatory system | Maintain blood pressure in hypotensive states | I10 | DRD2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Huntington's disease | F02.2, G10 | DRD2; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Emesis | R11 | DRD2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | DRD2; |
| I00-I99: Diseases of the circulatory system | Angina pectoris | I20 | DRD2; |
| I00-I99: Diseases of the circulatory system | Hypertension | I10-I16 | DRD1; DRD2; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperprolactinemia | E22.1 | DRD2; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Acromegaly | E22.0 | DRD2; |
| NA: NA | Itching | NA | DRD2; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Allergy | T78.4 | DRD2; |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | DRD2; |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | DRD1; DRD2; |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | DRD1; DRD2; |
| K00-K95: Diseases of the digestive system | Inflammatory bowel disease | K50, K51 | DRD2; |
| NA: NA | Inflammatory diseases | NA | DRD2; |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | DRD2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Advanced stage Parkinson's disease | F02.3, G20 | DRD2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Alcohol use disorders | F10.2 | DRD2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychotic disorders | F20-F29 | DRD1; DRD2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychosis | F20-F29 | DRD2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychiatric disorder | F01-F99 | DRD1; |
| A00-B99: Certain infectious and parasitic diseases | Bacterial infections | A00-B99 | DRD2; |
| NA: NA | Vomiting | NA | DRD2; |
| D50-D89: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism | Idiopathic thrombocytopenic purpura | D69.3 | DRD2; |
| J00-J99: Diseases of the respiratory system | Nasal congestion | J34.89 | DRD2; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Nausea | R11 | DRD2; |
>> Profiles of ingredients and activity landscape
>> Targets derived from weak experimental activities
